ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

AstraZeneca and Changchun GeneScience Pharmaceutical side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

AstraZenecaChangchun GeneScience Pharmaceutical
studies on the registry4,197112
open to participants now29847
phase 3 studies under way20011
reach primary completion within a year16918
programswith a study of their own in two years119+5 named only30

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseAstraZenecaChangchun GeneScience Pharmaceutical
Phase 1

AstraZeneca: 25 of its 119 programs at phase 1

  1. AZD4954phase 1
  2. AZD1613phase 1
  3. AZD1390phase 1
  4. Actinium Ac 225-DOTA-Anti-STEAP2 Monoclonal Antibody AZD2284phase 1
  5. ALXN2230phase 1

and 20 more — sign in to see them all

21%

Changchun GeneScience Pharmaceutical: 18 of its 30 programs at phase 1

  1. GENSCI098phase 1
  2. GENSCI142phase 1
  3. PEG-rhGH with new preparation (T)phase 1
  4. PEG-rhGH with present preparation (T)phase 1
  5. GENSCI128phase 1

and 13 more — sign in to see them all

60%
Phase 2

AstraZeneca: 47 of its 119 programs at phase 2

  1. AZD9550phase 2
  2. zadavotide guraxetanphase 2
  3. palacaparibphase 2
  4. Berzanoflastphase 2
  5. AZD7798phase 2

and 42 more — sign in to see them all

39%

Changchun GeneScience Pharmaceutical: 7 of its 30 programs at phase 2

  1. GENSCI048phase 2
  2. GENSCI134phase 2
  3. GS1-144phase 2
  4. GENSCI120phase 2
  5. GENSCI136phase 2

and 2 more — sign in to see them all

23%
Phase 3

AstraZeneca: 28 of its 119 programs at phase 3

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3

and 23 more — sign in to see them all

24%

Changchun GeneScience Pharmaceutical: 3 of its 30 programs at phase 3

  1. Cabergolinephase 3
  2. PEG-hGH Injectionphase 3
  3. leuprolide mesylatephase 3
10%
Approved, new studies

AstraZeneca: 19 of its 119 programs at approved, new studies

  1. durvalumabapproved, new study
  2. acalabrutinibapproved, new study
  3. trastuzumab deruxtecanapproved, new study
  4. osimertinibapproved, new study
  5. anifrolumabapproved, new study

and 14 more — sign in to see them all

16%

Changchun GeneScience Pharmaceutical: 2 of its 30 programs at approved, new studies

  1. Megestrol Acetateapproved, new study
  2. Human Growth Hormoneapproved, new study
7%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
AstraZeneca61 readouts · 16 phase 3

AstraZeneca, Nov ’26: 6 programs whose next study reaches primary completion

  1. elecoglipronphase 3 · Nov 18 · NCT07723833
  2. Elecoglipron Test formulation 1 Dose Aphase 1 · Nov 18 · NCT07723833
  3. Autologous dnTGF-BRII-armored Anti-STEAP2 CAR T-cells AZD0754phase 2 · Nov 24 · NCT06267729
  4. STEAP2-targeting Radioconjugate AZD2287phase 2 · Nov 24 · NCT06267729
  5. durvalumabapproved, new study · Nov 30 · NCT07081633

and 1 more — sign in to see them all

AstraZeneca, Dec ’26: 7 programs whose next study reaches primary completion, 2 in phase 3

  1. eculizumabapproved, new study · Dec 7 · NCT06724809
  2. AZD3974phase 1 · Dec 8 · NCT07290283
  3. baxdrostatphase 3 · Dec 10 · NCT07222917
  4. dapagliflozinapproved, new study · Dec 10 · NCT07222917
  5. benralizumabapproved, new study · Dec 23 · NCT05692180

and 2 more — sign in to see them all

AstraZeneca, Jan ’27: 12 programs whose next study reaches primary completion, 6 in phase 3

  1. laroprovstatphase 3 · Jan 4 · NCT07000136
  2. anifrolumabapproved, new study · Jan 6 · NCT05925803
  3. monalizumabphase 3 · Jan 8 · NCT05221840
  4. oleclumabphase 3 · Jan 8 · NCT05221840
  5. datopotamab deruxtecanphase 3 · Jan 11 · NCT06417814

and 7 more — sign in to see them all

AstraZeneca, Feb ’27: 7 programs whose next study reaches primary completion, 3 in phase 3

  1. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3 · Feb 1 · NCT06530849
  2. trastuzumab deruxtecanapproved, new study · Feb 10 · NCT06271837
  3. Berzanoflastphase 2 · Feb 11 · NCT07215702
  4. acalabrutinibapproved, new study · Feb 15 · NCT02972840
  5. zibotentanphase 3 · Feb 18 · NCT06087835

and 2 more — sign in to see them all

AstraZeneca, Mar ’27: 4 programs whose next study reaches primary completion

  1. AZD7760phase 2 · Mar 8 · NCT06749457
  2. AZD4954phase 1 · Mar 17 · NCT07812077
  3. AZD0543phase 1 · Mar 24 · NCT07824622
  4. Anti-Claudin 18.2 Antibody-drug Conjugate AZD4360phase 2 · Mar 31 · NCT06921928

AstraZeneca, Apr ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. AZD1043phase 1 · Apr 9 · NCT07511205
  2. camizestrantphase 3 · Apr 20 · NCT05774951
  3. ombetoxabartphase 2 · Apr 20 · NCT07285213

AstraZeneca, May ’27: 5 programs whose next study reaches primary completion, 2 in phase 3

  1. rilvegostomigphase 3 · May 4 · NCT04379596
  2. Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492phase 2 · May 5 · NCT06916806
  3. AZD1613phase 1 · May 22 · NCT07228364
  4. Budesonideapproved, new study · May 31 · NCT07073950
  5. formoterolapproved, new study · May 31 · NCT07073950

AstraZeneca, Jun ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. tozorakimabphase 3 · Jun 7 · NCT06932263
  2. ravulizumabapproved, new study · Jun 25 · NCT07308574
  3. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2 · Jun 30 · NCT06795022

AstraZeneca, Jul ’27: 3 programs whose next study reaches primary completion

  1. ALXN1920phase 2 · Jul 2 · NCT07157787
  2. AZD2389phase 2 · Jul 7 · NCT07610837
  3. SC rilvegostomig + rHuphase 1 · Jul 19 · NCT07161414

AstraZeneca, Aug ’27: 4 programs whose next study reaches primary completion

  1. ALXN2230phase 1 · Aug 9 · NCT07352423
  2. AZD0240phase 1 · Aug 30 · NCT06218914
  3. SC durvalumab + rHuphase 1 · Aug 30 · NCT07391670
  4. AZD6793phase 2 · Aug 31 · NCT07082738

AstraZeneca, Sep ’27: 2 programs whose next study reaches primary completion

  1. palacaparibphase 2 · Sep 29 · NCT05123482
  2. puxitatug samrotecanphase 3 · Sep 29 · NCT05123482

AstraZeneca, Oct ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. opemalirsenphase 2 · Oct 4 · NCT06824987
  2. cevolisiranphase 2 · Oct 11 · NCT06744647
  3. tarperprumigphase 2 · Oct 11 · NCT07160608
  4. torvutatug samrotecanphase 3 · Oct 15 · NCT07402915
  5. sodium zirconium cyclosilicateapproved, new study · Oct 30 · NCT07944378
Changchun GeneScience Pharmaceutical13 readouts · 3 phase 3

Changchun GeneScience Pharmaceutical, Nov ’26: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. Cabergolinephase 3 · Nov 21 · NCT07124221
  2. GENSCI134phase 2 · Nov 25 · NCT07016802

Changchun GeneScience Pharmaceutical, Dec ’26: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. polyethylene glycol-recombinant human growth hormonephase 2 · Dec 23 · NCT07260500
  2. Megestrol Acetateapproved, new study · Dec 31 · NCT07243379

Changchun GeneScience Pharmaceutical, Jan ’27: 2 programs whose next study reaches primary completion

  1. GENSCI142phase 1 · Jan 5 · NCT07663838
  2. GS1-144phase 2 · Jan 31 · NCT07491289

Changchun GeneScience Pharmaceutical, Feb ’27: 1 program whose next study reaches primary completion

  1. GENSCI136phase 2 · Feb 7 · NCT07366866
·

Changchun GeneScience Pharmaceutical, Apr ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. GENSCI155phase 1 · Apr 16 · NCT07638800
  2. Human Growth Hormoneapproved, new study · Apr 28 · NCT07691125

Changchun GeneScience Pharmaceutical, May ’27: 1 program whose next study reaches primary completion

  1. GENSCI161phase 1 · May 6 · NCT07476586
···

Changchun GeneScience Pharmaceutical, Sep ’27: 2 programs whose next study reaches primary completion

  1. GENSCI120phase 2 · Sep 0 · NCT07423533
  2. GENSCI098phase 1 · Sep 2 · NCT06569758

Changchun GeneScience Pharmaceutical, Oct ’27: 1 program whose next study reaches primary completion

  1. GENSCI164phase 1 · Oct 25 · NCT07790783
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 20, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

AstraZeneca

New programs 2

Reached a new phase 1

Study stopped 0

None

Primary completion later 23

Changchun GeneScience Pharmaceutical

New programs 2

Reached a new phase 1

  • GENSCI136phase 2 · Oct 27 · Autoimmune Diseases

Study stopped 1

  • GENSCI122phase 1 · terminated Nov 17 · none of its studies left running“The sponsor adjusted its research and development strategy” · NCT06772415

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 7 in all. A program counts in each condition its studies name most.

ConditionAstraZenecaChangchun GeneScience Pharmaceutical
Carcinoma, Non-Small-Cell Lungboth · compare here

AstraZeneca in Carcinoma, Non-Small-Cell Lung: 18 programs

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. ceralasertibphase 3

and 13 more — sign in to see them all

Their studies: AstraZeneca’s studies of Carcinoma, Non-Small-Cell Lung in search

Changchun GeneScience Pharmaceutical in Carcinoma, Non-Small-Cell Lung: 1 program

  1. Megestrol Acetateapproved, new study

Their studies: Changchun GeneScience Pharmaceutical’s studies of Carcinoma, Non-Small-Cell Lung in search

Prostatic Neoplasmsboth · compare here

AstraZeneca in Prostatic Neoplasms: 13 programs

  1. saruparibphase 3
  2. capivasertibphase 3
  3. zibotentanphase 3
  4. Actinium-225phase 3
  5. zadavotide guraxetanphase 2

and 8 more — sign in to see them all

Their studies: AstraZeneca’s studies of Prostatic Neoplasms in search

Changchun GeneScience Pharmaceutical in Prostatic Neoplasms: 1 program

  1. leuprolide mesylatephase 3

Their studies: Changchun GeneScience Pharmaceutical’s studies of Prostatic Neoplasms in search

Neoplasmsboth · compare here

AstraZeneca in Neoplasms: 6 programs

  1. saruparibphase 3
  2. ceralasertibphase 3
  3. Leucovorinphase 2
  4. Ramucirumabphase 2
  5. AZD1390phase 1

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Neoplasms in search

Changchun GeneScience Pharmaceutical in Neoplasms: 1 program

  1. Megestrol Acetateapproved, new study

Their studies: Changchun GeneScience Pharmaceutical’s studies of Neoplasms in search

Arthritis, Rheumatoidboth · compare here

AstraZeneca in Arthritis, Rheumatoid: 2 programs

  1. surovatamigphase 3
  2. AZD1163phase 2

Their studies: AstraZeneca’s studies of Arthritis, Rheumatoid in search

Changchun GeneScience Pharmaceutical in Arthritis, Rheumatoid: 2 programs

  1. GENSCI048phase 2
  2. GENSCI120phase 2

Their studies: Changchun GeneScience Pharmaceutical’s studies of Arthritis, Rheumatoid in search

Neoplasm Metastasisboth · compare here

AstraZeneca in Neoplasm Metastasis: 3 programs

  1. saruparibphase 3
  2. camizestrantphase 3
  3. trastuzumab deruxtecanapproved, new study

Their studies: AstraZeneca’s studies of Neoplasm Metastasis in search

Changchun GeneScience Pharmaceutical in Neoplasm Metastasis: 1 program

  1. Megestrol Acetateapproved, new study

Their studies: Changchun GeneScience Pharmaceutical’s studies of Neoplasm Metastasis in search

Acromegalyboth · compare here

AstraZeneca in Acromegaly: 1 program

  1. ALXN2420phase 2

Their studies: AstraZeneca’s studies of Acromegaly in search

Changchun GeneScience Pharmaceutical in Acromegaly: 1 program

  1. Cabergolinephase 3

Their studies: Changchun GeneScience Pharmaceutical’s studies of Acromegaly in search

Fastingboth · compare here

AstraZeneca in Fasting: 1 program

  1. balcinrenonephase 3

Their studies: AstraZeneca’s studies of Fasting in search

Changchun GeneScience Pharmaceutical in Fasting: 1 program

  1. Cabergolinephase 3

Their studies: Changchun GeneScience Pharmaceutical’s studies of Fasting in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetAstraZenecaChangchun GeneScience Pharmaceutical
EGFRosimertinibruleGENSCI139rule
ERBB2trastuzumab deruxtecanruleGENSCI139rule
A target, or a pathogen for a vaccine, known for: AstraZeneca 68 of 119 · Changchun GeneScience Pharmaceutical 7 of 30 programs (36 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (AstraZeneca: 5).